加减血府逐瘀汤联合达比加群酯治疗非瓣膜房颤的临床观察及安全性评价  

Clinical Observation and Safety Evaluation of Modified Xuefu Zhuyu Decoction Combined with Dabigatran Etexilate in the Treatment of Non-valvular Atrial Fibrillation

作　　者：于萍[1] 

机构地区：[1]北京市和平里医院,北京100013

出　　处：《中医药信息》2018年第1期108-110,共3页Information on Traditional Chinese Medicine

摘　　要：目的:观察加减血府逐瘀汤联合达比加群酯治疗非瓣膜房颤的临床疗效。方法:将符合纳入标准的80例血瘀型非瓣膜房颤患者随机分为对照组(40例)和治疗组(40例)两组,观察两组患者短暂性脑缺血发作(TIA)、脑栓塞、肺栓塞、脑出血及上消化道出血的发生率及治疗前后患者血凝参数、血常规、尿常规、便常规、肝功能和肾功能及中医症候总积分的变化。结果:治疗后,对照组总有效率为62.5%(显效6例,有效19例,无效15例);治疗组总有效率为85.0%(显效11例,有效23例,无效6例);治疗组疗效显著优于对照组(P<0.05)。治疗组治疗后患者的上消化道出血的发生率、中医症候总积分显著降低,且效果明显优于对照组(P<0.05)。但两组患者在TIA及脑栓塞方面未见明显差异。此外,本研究未见血常规、尿常规、便常规、肝功能和肾功能明显异常,表明药物安全性较好。结论:加减血府逐瘀汤联合西药达比加群酯治疗,可显著改善非瓣膜房颤患者的临床症状,明显提高疗效,值得临床推广运用。Objectives: To observe the clinical efficacy of modified Xuefu Zhuyu decoction combined with Dabigatran Etexilate in the treatment of non-valvular atrial fibrillation. Methods: 80 patients suffering from non-valvular atrial fibrillation of blood stasis type were randomly assigned to the control group( n = 40) and the observation group( n = 40). The incidences of transient ischemic attack( TIA),cerebral embolism,pulmonary embolism,cerebral hemorrhage,and upper gastrointestinal bleeding were observed,and parameters of coagulation,blood routine test,urine routine test,stool routine test,liver function,and kidney function,as well as TCM syndrome integral were assessed before and after the treatment. Results: After the treatment,the total effective rate of the control group was 62. 5%( 6 excellent cases,19 effective cases,15 invalid cases),and the total effective rate of the observation group was 85. 0%( 11 excellent cases,23 effective cases,6 invalid cases); of which,the observation group was superior to the control group( P < 0. 05). The observation group was also better than the control group in terms of reducing the incidence of upper gastrointestinal bleeding and decreasing the scores of TCM syndrome integral( P < 0. 05). However,there were no significant difference in improvement of TIA and cerebral embolism between the two groups. There were no obvious adverse reactions in terms of blood routine test,urine routine test,stool routine test,liver function,and kidney function,which indicated that the medication had a good safety. Conclusions: The therapy of modified Xuefu Zhuyu decoction combined with Dabigatran Etexilate can significantly improve the clinical signs of non-valvular atrial fibrillation and notably enhance the clinical effectiveness,and it is worth clinical appliaction.

关 键 词：非瓣膜房颤 血瘀型 血府逐瘀汤 中医药治疗 

分 类 号：R285[医药卫生—中药学]